D3 Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
D3 Bio, Inc. - overview
Established
2020
Location
Wuxi, Jiangsu, China
Primary Industry
Biotechnology
About
Founded in 2020 and based in Wuxi, China, D3 Bio (Wuxi) Co. , Ltd. , trading as D3 Bio, Inc. , is a biotechnology company that researches and develops therapies for tumors and immune precision.
George Chen, the company's CEO, has held senior global management positions in research, drug development and administration at leading institutions such as the National Institutes of Health, and multinational pharmaceutical companies such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pepperl+Gene and AstraZeneca. In December 2025, the firm raised USD 108 million in series B funding. The company develops targeted therapies for cancer and immune-related diseases, including programs advancing into clinical evaluation across major markets. Its pipeline includes candidates designed to address tumor-driving mutations and immune pathways.
The company generates revenue from out-licensing agreements, milestone payments and commercialization of approved therapeutics. The company plans to accelerate global Phase III clinical studies for its lead candidate and expand development across its oncology and immunology programs.
Current Investors
Hong Shan, Temasek Holdings, Boyu Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals
Website
www.d3bio.com/
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.